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Abstract 
Objective: Rhenium is one of the most valuable elements for internal 
radiotherapy because 186Re and 188Re have favorable physical 
characteristics. However, there are problems when proteins such as 
antibodies are used as carriers of 186/188Re. Labeling methods that use 
bifunctional chelating agents such as MAG3 require the conjugation of the 
186/188Re complex to protein after radiolabeling with the bifunctional 
chelating agent. These processes are complicated. Therefore, we planned 
the preparation by a simple method and evaluation of a stable 
186/188Re-labeled antibody. For this purpose, we selected 186/188Re(I) 
tricarbonyl complex as a chelating site. In this study, A7 (an IgG1 murine 
monoclonal antibody) was used as a model protein. 186/188Re-labeled A7 
was prepared by directly reacting a 186/188Re(I) tricarbonyl precursor, 
[186/188Re(CO)3(H2O)3]+, with A7. We then compared the biodistribution of 
186/188Re-labeled A7 in tumor-bearing mice with 125I-labeled A7. 
Methods: For labeling A7, [186/188Re(CO)3(H2O)3]+ was prepared according 
to a published procedure. 186/188Re-labeled A7 (186/188Re-(CO)3-A7) was 
prepared by reacting [186/188Re(CO)3(H2O)3]+ with A7 at 43ºC for 2 hours. 
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Biodistribution experiments were performed by the intravenous 
administration of 186/188Re-(CO)3-A7 solution into tumor-bearing mice. 
Results: 186Re-(CO)3-A7 and 188Re-(CO)3-A7 were prepared with 
radiochemical yields of 23% and 28%, respectively. After purification by a 
PD-10 column, 186/188Re-(CO)3-A7 showed a radiochemical purity of over 
95%. In biodistribution experiments, 13.1% and 13.2% of the injected 
dose/g of 186Re-(CO)3-A7 and 188Re-(CO)3-A7, respectively, accumulated 
in the tumor 24 hours postinjection, and the tumor-to-blood ratios were 
over 2.0 at the same timepoint. Meanwhile, uptake of 125I-A7 in the tumor 
was almost the same as those of 186/188Re-(CO)3-A7 at 24 hours 
postinjection. Blood clearances of 186/188Re-(CO)3-A7 were faster than that 
of 125I-A7. 
Conclusion: 186/188Re-labeled A7 showed high uptakes in the tumor. 
However, further modification of the labeling method would be necessary 
to improve radiochemical yields and their biodistribution. 
 
Keywords: rhenium, radioimmunotherapy, antibody, tricarbonyl 
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Introduction 
      Radioimmunotherapy with radiolabeled monoclonal antibodies 
(mAb) has great potential to be a good treatment modality for cancer 
patients. In particular, radioimmunotherapy in B-cell non-Hodgkin’s 
lymphoma targeting the CD20 antigen, which is found on the B-cell 
surface, has clearly demonstrated its efficacy [1,2]. Consequently, 90Y 
ibritumomab tiuxetan (Zevalin) and 131I tositumomab (Bexxar), both 
targeting the CD20 antigen, have been approved by the United States Food 
and Drug Administration for treatment of refractory or relapsed low-grade, 
follicular, or transformed B-cell non-Hodgkin’s lymphoma [3,4]. Both 
radiopharmaceuticals have been shown to produce high response rates, but 
they also have some shortcomings as radionuclides. 131I emits a high energy 
gamma ray, 364 keV, that is not ideal for imaging and exposes patients to 
unnecessary radiation. Meanwhile, because 90Y is a pure beta emitter, 
imaging is difficult with 90Y-mAb and dosimetry should be performed with 
111In-mAb before the 90Y-mAb therapy. However, 111In-mAb might not 
accurately predict the dosimetry of 90Y-mAb because it has been reported 
that 111In-mAb did not parallel the uptake of 86Y-mAb in bone [5]. 
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      Rhenium has two useful radionuclides for radionuclide therapy, 
186Re and 188Re. 186Re and 188Re are currently considered to be appropriate 
candidates for therapeutic applications due to their favorable nuclear 
properties [6,7]. Both rhenium radioisotopes decay with the emission of not 
only beta particles for therapy but also gamma rays, which are suitable for 
external detection with gamma cameras: 186Re (t1/2 = 3.68 d, β-max =1.07 
MeV, γ = 137 keV) and 188Re (t1/2 = 16.98 h, β-max =2.12 MeV, γ = 155 keV). 
Additionally, in the case of 188Re, a further advantage in clinical use is that 
188Re is conveniently produced from a transportable, in-house 
alumina-based 188W/188Re generator, similar to a 99Mo/99mTc generator 
[8,9]. 
      Previous reports have demonstrated the usefulness of 186/188Re 
radionuclide therapy. However, there are problems when proteins such as 
antibodies are used as carriers of 186/188Re. A direct label method is not 
ideal because of the instability of labeled mAb, especially in the case of 
186Re [10]. The mercaptoacetylglycylglycylglycine (MAG3) ligand forms a 
stable 186Re-MAG3 complex [11]; the usefulness of 186Re-MAG3-mAb has 
been demonstrated in preclinical studies [12,13]. However, the labeling 
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method using bifunctional chelating agents such as the N3S (MAG3) and 
N2S2 (MAMA) ligand requires conjugation with the 186/188Re-complex to 
mAb after radiolabeling because this radiolabeling procedure requires 
severe conditions, such as heating and a non-neutral pH [14,15]. These 
complicated processes limit the clinical utility of radiolabeled mAb. Thus, 
we planned the preparation by a simple method and evaluation of a stable 
186/188Re-labeled protein. For this purpose, we selected 186/188Re(I) 
tricarbonyl complex as a chelating site. In this study, A7 (an IgG1 murine 
mAb) was used as a model protein, and 186/188Re-labeled A7 were prepared 
by directly reacting a 186/188Re(I) tricarbonyl precursor, 
[186/188Re(CO)3(H2O)3]+, with A7. Then, in vitro stability experiments and 
biodistribution experiments in tumor-bearing mice were performed.  
 
Materials and Methods 
Materials 
      186Re and 188W were supplied by the Japan Atomic Energy Agency 
(Tokai-mura, Japan) as 186ReO4- and 188WO42- [16]. Alumina acid grade 
(100-200 mesh) alumina (ICN, Irvine, CA) was used as an adsorbent for 
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the 188W/188Re generator. Silver cation exchange cartridges (Ag Plus) and 
anion exchange cartridges (SepPak QMA Light) were purchased from 
Alltech Associates, Inc. (Deerfield, IL) and Waters Corporation (Milford, 
MA), respectively. 188ReO4- was eluted from a 188W/188Re generator using 
saline. The radioactive elution (5 mL) was condensed to a total of 400 μL 
using the method reported previously [8,9]. A7, an immunoglobulin G1 
murine mAb that recognizes the 45-kDa glycoprotein in human colon 
cancer, was used. A7 reacts with most colorectal cancers [17]. Isolink kits 
for preparing [186/188Re(CO)3(H2O)3]+ were obtained from Mallinckrodt (St 
Louis, MO). [125I]Sodium iodide was purchased from PerkinElmer 
(Waltham, MA). Radiolabeling of A7 with 125I was performed by the 
chloramine-T method [18]. Other reagents were of reagent grade and used 
as received.  
      The radiochemical purities of 186/188Re- and 125I-labeled A7 were 
determined by thin layer chromatography (TLC) and cellulose acetate 
electrophoresis (CAE) (Separax-SP; Joko Co. Ltd., Tokyo, Japan). TLC 
analyses were performed with silica plates (Art 5553, Merck, Darmstadt, 
Germany) with a mixture of 99% methanol and 1% concentrated HCl as a 
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developing solvent. CAE was run at an electrostatic field of 1.0 mA/cm for 
20 minutes in veronal buffer (I = 0.06, pH 8.6).  
 
Preparation of 186/188Re-labeled A7 (186/188Re-(CO)3-A7) 
      An intermediate of 186/188Re-labeled mAb, [186/188Re(CO)3 (H2O)3]+, 
was prepared using an Isolink kit according to the method reported 
previously [19,20]. Namely, a mixture of 400 μL 186/188ReO4- and 6 μL 
concentrated phosphoric acid was added to an Isolink kit to which 6 mg 
BH3·NH3 (Aldrich, Milwaukee, WI) had previously been added. The 
reaction mixture was heated at 65ºC for 15 minutes with a 20 mL syringe 
inserted to balance the pressure caused by gas production during the 
reaction. After the 186/188Re tricarbonyl intermediate solution was adjusted 
to about 7 pH, 200 μL of this solution was added to 80 μL of the A7 mAb 
solution (14.7 mg/mL). After 2 hours of incubation at 43ºC, this reaction 
mixture was purified by a PD-10 column (GE Healthcare UK Ltd., 
Buckinghamshire, England) with saline as the eluate. 
 
In Vitro Stability 
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    To evaluate its stability, 188Re-(CO)3-A7 in saline solution was 
incubated at 37˚C. After incubation for 24 hours, a sample was drawn and 
its radioactivity was analyzed by CAE and TLC. In addition, 
188Re-(CO)3-A7 solutions were diluted 10-fold with a 0.1 M solution of 
histidine or freshly prepared murine plasma, and the solutions were 
incubated at 37˚C. After 1, 3, and 24 hours incubation, the radioactivity of 
each sample was analyzed by TLC. 
 
Biodistribution in tumor-bearing mice 
      Experiments with animals were conducted in accordance with the 
Guidelines for the Care and Use of Laboratory Animals of Kanazawa 
University. The animals were housed with free access to food and water at 
23°C with a 12-hour alternating light/dark schedule. LS180 human colon 
carcinoma cells were obtained from ATCC (Manassas, VA) and grown in 
cell culture dishes in Eagle’s minimum essential medium with phenol red, 
10% heat-inactivated fetal calf serum, 100 μg/mL glutamine, 100 units/mL 
penicillin, and 100 μg/mL streptomycin. The cells were cultured in a 
humidified atmosphere of 95% air and 5% carbon dioxide at 37°C. They 
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were then released from the dishes by treatment with 0.05% trypsin/EDTA. 
Next, to produce tumors, the mice to be inoculated were anesthetized with 
pentobarbital and approximately 5 × 106 cells were injected subcutaneously 
into the right shoulder of 4-week-old BALB/c nu/nu female mice (15-19 g). 
Biodistribution experiments were performed approximately 8 days 
postinoculation, i.e., the time required for the tumors to reach a palpable 
size. Groups of four or five mice were administered 100 μL 
186Re-(CO)3-A7, 188Re-(CO)3-A7, or 125I-A7 (7.4 kBq, A7:100 μg, 
respectively) intravenously and sacrificed at 1 and 24 hours postinjection. 
Tissues of interest were removed and weighed, and radioactivity counts 
were determined with an Auto Well Gamma System (ARC-380; Aloka, 




Preparation of 186/188Re-(CO)3-A7 
      In TLC analyses, 186/188Re-(CO)3-A7 remained at the original 
position (Rf = 0), while an intermediate, [186/188Re(CO)3(H2O)3]+, and the 
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free perrhenate (186/188ReO4-) migrated to Rf = 0.2-0.4 and Rf = 0.7-0.8, 
respectively [20]. In CAE analyses, intact A7 migrated to the 2-2.5 cm 
anode from the origin, which was determined by Ponceau S dye, and 
186/188Re-(CO)3-A7 also migrated to the 2-2.5 cm anode (Figure 1), while 
colloidal 186/188Re remained at the origin. The radiolabeling yield of 
[188Re(CO)3(H2O)3]+ was 41%. 186Re-(CO)3-A7 and 188Re-(CO)3-A7 were 
prepared with radiochemical yields of 23% and 28%, respectively. After 
purification using a PD-10 column, 186Re-(CO)3-A7 and 188Re-(CO)3-A7 
showed a radiochemical purity of over 95%. 
 
In Vitro Stability 
      After incubation in saline for 24 hours, about 93% of the 
188Re-(CO)3-A7 remained intact. In murine plasma, over 90% of 
radioactivity existed in a protein fraction for 24 hours, indicating that the 
188Re-(CO)3-A7 is not degraded to 188ReO4- in plasma. When challenged 
with an excess of histidine, part of the radioactivity dissociated from 
188Re-(CO)3-A7 (Figure 2). 
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Biodistribution in tumor-bearing mice 
      The biodistributions of 186Re-(CO)3-A7, 188Re-(CO)3-A7, and 
125I-A7 in tumor-bearing mice are listed in Tables 1-3. As we expected, 
both radiorhenium-labeled A7 had almost identical biodistribution. 
186Re-(CO)3-A7 and 188Re-(CO)3-A7 showed high uptakes in the tumors, 
amounting to 13.1% and 13.2% at 24 hours postinjection, respectively. 
Meanwhile, uptake of 125I-A7 in the tumor was almost the same as those of 
186/188Re-(CO)3-A7 at 24 hours postinjection. Blood clearances of 
186/188Re-(CO)3-A7 were faster than that of 125I-A7. 186/188Re-(CO)3-A7 
showed that the tumor/blood ratios were over 2.0 at 24 hours postinjection, 
but the tumor/blood ratio of 125I-A7 was approximately 1.0. 
 
Discussion 
      We hypothesize that 186/188Re(CO)3 core binds endogenous histidine 
residue in an antibody when [186/188Re(CO)3(H2O)3]+ is used to label the 
antibody. In our preliminary experiments, we labeled H-His-OMe with 
[186Re(CO)3(H2O)3]+ at room temperature, 45˚C, or 100˚C. As a result, the 
radiochemical yield increased in a reaction temperature-dependent manner. 
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In this study, A7 was reacted with [186/188Re(CO)3(H2O)3]+ at 43˚C because 
higher temperatures damage the antibody. Radiochemical yields of 
186/188Re-labeled A7 were less than 30%. For clinical use, the radiochemical 
purity should be over 95% without purification. We suppose that some 
sequences, such as an oligohistidine sequence, could be inserted into the 
antibody to improve the radiochemical yield. Tait et al reported that 
(His)6-inserted annexin V had a better radiochemical yield compared with 
those of (His)3-inserted annexin V and wild-type annexin V when annexin 
V was labeled with [99mTc(CO)3(H2O)3]+ [21]. Another cause of low 
radiochemical yields of 186/188Re-labeled A7 could be low yields of 
[186/188Re(CO)3(H2O)3]+. In this study, the radiochemical yield of 
[188Re(CO)3(H2O)3]+ was only 41%. Recently, higher yields of the 
preparation of the precursor, [188Re(CO)3(H2O)3]+, were reported [22,23]. 
We assume that using the new method for preparing 
[186/188Re(CO)3(H2O)3]+ in future studies would also improve the 
radiochemical yields of 186/188Re-labeled A7. 
      The high stability of 188Re-(CO)3-A7 in saline and almost no 
degradation to 188ReO4- in plasma were shown in in vitro experiments. 
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Since accumulation in the stomach is an index of ReO4- in biodistribution 
studies [24], low radioactivity levels in the stomach after injection of 
186/188Re-(CO)3-A7 indicate little decomposition to 186/188ReO4- in vivo. In a 
recent study, Chen et al. prepared a 188Re-labeled antibody 
(188Re(I)-trastuzumab) by a similar method [23]. 188Re(I)-trastuzumab 
showed high stability in vitro and low stomach accumulation in 
tumor-bearing mice. These studies strongly support the validity of our 
results. 
      In other previous studies, it was reported that a radioiodine-labeled 
antibody, 88Y-isothiocyanatobenzyl-DTPA-antibody, and 
186Re-MAG3-antibody showed similar blood clearances [25,26]. However, 
in this study, the radioactivity (%dose/g) in blood at 24 hr postinjection of 
186Re-(CO)3-A7, 188Re-(CO)3-A7, and 125I-A7 were 6.2 ±0.3, 5.9 ±0.8, and 
13.9 ±3.5, respectively. That is, 186/188Re-(CO)3-A7 showed faster blood 
clearance compared with that of 125I-A7 in the biodistribution experiments. 
These results might indicate that 186/188Re detached from A7 in the blood 
flow. There is a possibility that the binding of the 186/188Re-(CO)3 core to 
A7 is not strong, so some molecules in the blood might take the 
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186/188Re-(CO)3 core from 186/188Re-(CO)3-A7. Actually, when 
188Re-(CO)3-A7 was challenged with an excess of histidine, part of the 
radioactivity dissociated from 188Re-(CO)3-A7. In this experiment, the 
radiochemical purity of 188Re-(CO)3-A7 decreased to around 60% after 3 
hours incubation. However, after 24 hours incubation, the radiochemical 
purity of 188Re-(CO)3-A7 was almost same as that after 3 hours incubation. 
These results might indicate that there are strong and weak bindings of the 
188Re-(CO)3 core to an A7 antibody in purified 188Re-(CO)3-A7 because the 
188Re-(CO)3 core does not bind to a specific site in an antibody. Recently, 
the biodistribution of [188Re(CO)3(H2O)3]+ was reported [27]. The 
radioactivity in blood, liver, and kidney at 24 hours postinjection of 
[188Re(CO)3(H2O)3]+ were 3.13 ±0.52, 9.65 ±1.40, and 9.62 ±0.09, 
respectively. Taking into account the biodistribution at 24 hours 
postinjection of 186/188Re-(CO)3-A7 in this study, these results are also not 
inconsistent with our hypothesis. 
      Faster blood clearance is advantageous for fewer side effects 
because myelosuppression is the chief side effect associated with 
radioimmunotherapy [28]. However, faster blood clearance compromises 
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the accumulation of radioactivity in tumors. In sum, although diagnostic 
radiopharmaceuticals should be better because they need a high 
tumor/blood ratio at an earlier time postinjection, therapeutic 
radiopharmaceuticals might be unfavorable because high accumulation and 
long retention in tumors is preferred for a better therapeutic effect. As 
mentioned above, we suppose that insertion of an oligohistidine sequence 
could improve radiochemical yield. Additionally, insertion could also be 
effective from the point of view of improving the in vivo stability and 
biodistribution of 186/188Re-labeled antibodies. 
 
Conclusion 
      186/188Re-labeled A7 showed high uptakes in tumors the same as that 
of 125I labeled A7. However, further modifications of the labeling method 
would be necessary in order to improve radiochemical yields and their 
biodistribution. 
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Figure Captions 
Figure 1. Profiles of 188Re-(CO)3-A7 and intact A7 (Ponceau S dye) on 
cellulose acetate electrophoresis. 
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Table 1. Biodistribution of radioactivity after intravenous administration of 
186Re-(CO)3-A7 in mice. 
 Time after administration 
Tissue 1 h 24 h 
Blood 24.8 (1.1) 6.2 (0.3) 
Tumor 5.1 (0.7) 13.1 (1.8) 
Liver 18.5 (0.4) 9.7 (0.8) 
Kidney 13.8 (0.4) 9.0 (1.1) 
Intestine 1.5 (0.3) 2.0 (0.2) 
Spleen 7.8 (1.0) 4.5 (0.9) 
Pancreas 1.1 (0.1) 0.9 (0.0) 
Lung 11.8 (2.5) 3.8 (0.5) 
Heart 4.4 (0.6) 1.8 (0.1) 
Stomacha 0.4 (0.0) 0.2 (0.0) 
Muscle 0.9 (0.4) 0.8 (0.1) 
Data are expressed as % injected dose per gram tissue. Each value 
represents the mean (SD) of four or five animals. 
a Data are expressed as % injected dose. 
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Table 2. Biodistribution of radioactivity after intravenous administration of 
188Re-(CO)3-A7 in mice. 
 Time after administration 
Tissue 1 h 24 h 
Blood 27.6 (1.8) 5.9 (0.8) 
Tumor 6.0 (1.7) 13.2 (1.7) 
Liver 18.9 (2.8) 9.7 (0.8) 
Kidney 14.8 (1.7) 8.9 (0.4) 
Intestine 1.8 (0.2) 2.0 (0.3) 
Spleen 8.3 (0.8) 4.0 (0.7) 
Pancreas 1.5 (0.2) 0.8 (0.0) 
Lung 12.6 (2.2) 3.2 (0.4) 
Heart 5.6 (0.5) 1.6 (0.3) 
Stomacha 0.9 (0.2) 0.3 (0.1) 
Muscle 0.8 (0.2) 0.5 (0.1) 
Data are expressed as % injected dose per gram tissue. Each value 
represents the mean (SD) of four or five animals. 
a Data are expressed as % injected dose. 
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Table 3. Biodistribution of radioactivity after intravenous administration of 
125I-A7 in mice. 
 Time after administration 
Tissue 1 h 24 h 
Blood 36.7 (4.3) 13.6 (2.1) 
Tumor 3.5 (0.7) 13.9 (3.5) 
Liver 10.7 (4.5) 3.4 (1.0) 
Kidney 8.3 (1.4) 2.9 (0.7) 
Intestine 1.6 (0.3) 1.0 (0.3) 
Spleen 7.5 (3.2) 2.5 (0.8) 
Pancreas 1.3 (0.4) 1.2 (0.2) 
Lung 19.8 (2.5) 7.8 (1.2) 
Heart 6.9 (1.0) 3.1 (0.5) 
Stomacha 1.2 (0.2) 1.0 (0.4) 
Muscle 0.9 (0.2) 0.8 (0.1) 
Data are expressed as % injected dose per gram tissue. Each value 
represents the mean (SD) of four animals. 
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